AI Terminal
Vetoquinol SA
Report Publication Announcement • Dec 15, 2021
1747_iss_2021-12-15_5197fa08-bf36-4e00-a0ea-184fdca4b9bd.pdf
Report Publication Announcement
Open in ViewerOpens in native device viewer
FINANCIAL RELEASE
Lure December 15 th, 2021
2022 CALENDAR OF FINANCIAL COMMUNICATION
Vetoquinol published its calendar of financial communication for 2022.
| 2021 Annual revenues (after market) |
|---|
| 2021 Annual results (before market) |
| 2022 First quarter revenues (after market) |
| Annual shareholders' meeting |
| Dividend distribution |
| 2022 First semester revenues (after market) |
| 2022 First semester results (after market) |
| 2022 Third quarter revenues (after market) |
| 2022 Annual revenues (after market) |
FOR MORE INFORMATION, CONTACT:
VETOQUINOL
Investor Relations Fanny Toillon Tel.: +33 (0)3 84 62 59 88 [email protected]
KEIMA COMMUNICATION
Investor & Media Relations Emmanuel Dovergne Tel.: +33 (0) 1 56 43 44 63 [email protected] Next update: 2021 Annual revenues, January 20th, 2022 after market close
ABOUT VETOQUINOL
Vetoquinol is a leading global animal health company that supplies drugs and nonmedicinal products for the livestock (cattle and pigs) and pet (dogs and cats) markets. As an independent pure player, Vetoquinol designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region. Since its foundation in 1933, Vetoquinol has pursued a strategy combining innovation with geographical diversification. The Group's hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high potential growth markets. Vetoquinol employed 2,540 people as of September 30th, 2021. Vetoquinol has been listed on Euronext Paris since 2006 (symbol: VETO). The Vetoquinol share is eligible for the French PEA and PEA-PME personal equity plans.
VETOQUINOL Magny-Vernois 70200 Lure - France
www.vetoquinol.com